<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766996</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002021</org_study_id>
    <nct_id>NCT04766996</nct_id>
  </id_info>
  <brief_title>PROUD Study - Preventing Opioid Use Disorders</brief_title>
  <official_title>PROUD Study - Preventing Opioid Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to pilot an opioid free anesthetic protocol for patients&#xD;
      undergoing total hip replacement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to pilot an opioid free anesthetic protocol for patients&#xD;
      undergoing total hip replacement. The study team identified alternative pharmacologic methods&#xD;
      to block pain pathways to reduce or even eliminate the need for opioids in the intra- and&#xD;
      postoperative periods, with the goal of decreasing or eliminating exposure to opioids. A&#xD;
      secondary objective is to assess two core competencies for interprofessional collaborative&#xD;
      practice (Interprofessional Communication and Teams; and Teamwork) within the&#xD;
      interprofessional care team implementing the opioid free protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Matched Prospective Case with Retrospective Control Study and Staff Survey</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total post-operative opioid requirements</measure>
    <time_frame>Up to 5 weeks</time_frame>
    <description>Total post-operative opioid requirements (opioid dose) will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Nebraska Interprofessional Education Attitude Scale (NIPEAS) score</measure>
    <time_frame>Prior to protocol implementation (baseline), halfway through the recruitment period (2 months) and after the last participant has been discharged from the hospital (4 months)</time_frame>
    <description>The survey will be provided to all consented perioperative suite professional staff. The NIPEAS is a 19-item questionnaire assessing attitudes related to interprofessional collaboration. The items are rated from 1=Strongly Agree to 5=Strongly Disagree.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Anesthesia</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective study participants undergoing unilateral total hip replacement surgery and non-opioid drug regimen perioperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective control underwent opioid drug regimen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Retrospective controls that underwent unilateral total hip replacement surgery and used opioid drug regimen perioperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Professional Staff</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Staff that participate in the implementation of the opioid free surgical protocol will be completing team assessment surveys seeking their opinion about interprofessional teamwork and communication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Guided mindfulness exercises</intervention_name>
    <description>Guided Meditation twice daily</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self-administered aromatherapy</intervention_name>
    <description>Self-administered aromatherapy every 6 hours and at bedtime</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baby aspirin</intervention_name>
    <description>Baby aspirin 81mg: Twice daily for 6 weeks after surgery</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tylenol/Acetaminophen</intervention_name>
    <description>Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin 25mg:&#xD;
Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 5mg: Daily for three weeks after surgery</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>Meloxicam 7.5mg:&#xD;
Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prilosec</intervention_name>
    <description>Prilosec 20mg:&#xD;
Daily for two weeks before surgery; Daily for for two weeks after surgery</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voltaren</intervention_name>
    <description>Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zofran</intervention_name>
    <description>Zofran 4 mg pre-operative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pepcid</intervention_name>
    <description>Pepcid 20 mg pre-operative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reglan</intervention_name>
    <description>Reglan 10 mg pre-operative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Versed</intervention_name>
    <description>Versed 2 mg pre-operative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol 10-125 mcg/kg/min intraoperative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ancef</intervention_name>
    <description>Ancef 2-3 gm weight-based dosing intraoperative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (TXA)</intervention_name>
    <description>Tranexamic Acid (TXA) 2 gm intraoperative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decadron</intervention_name>
    <description>Decadron 10 mg intraoperative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine hydrochloride</intervention_name>
    <description>Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toradol</intervention_name>
    <description>Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative</description>
    <arm_group_label>Prospective cases undergoing non-opioid drug regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Intervention group:&#xD;
&#xD;
        - Prospective study participants undergoing unilateral total hip replacement surgery&#xD;
        between the months of February - May 2021&#xD;
&#xD;
        Control:&#xD;
&#xD;
        - Retrospective controls selected from the Emory Healthcare System Clinical Data Warehouse&#xD;
        that underwent unilateral total hip replacement surgery between the months of February -&#xD;
        May 2020&#xD;
&#xD;
        Professional Staff:&#xD;
&#xD;
        - All staff that participate in the implementation of the opioid free surgical protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants that do not speak English will not be eligible for participation in the&#xD;
             study.&#xD;
&#xD;
          -  Individuals less than 18 years of age will not be included for participation in the&#xD;
             study.&#xD;
&#xD;
          -  Individuals with cognitive impairment or the inability to provide informed consent&#xD;
             will not be included in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wiltse Nicely, PhD, CRNA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Wiltse Nicely, PhD, CRNA</last_name>
    <phone>4047276946</phone>
    <email>kelly.wiltse.nicely@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Orthopaedic and Spine Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Wiltse Nicely, PhD, CRNA</last_name>
      <email>kelly.wiltse.nicely@emory.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Kelly Wiltse Nicely</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hip replacement</keyword>
  <keyword>Opiod free</keyword>
  <keyword>Perioperative period</keyword>
  <keyword>Team work</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in peer reviewed publication(s) will be shared after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Available beginning 6 months and ending 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.&#xD;
Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in Emory University's data warehouse but without investigator support other than deposited metadata. Information regarding the Emory Dataverse can be found at: http://sco.library.emory.edu/dataverse/index.html</ipd_access_criteria>
    <ipd_url>http://sco.library.emory.edu/dataverse/index.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

